Kymanox Announces Evan Edwards as President
May 06 2024 - 11:16AM
Kymanox®, a leading provider of product
development, engineering, quality, regulatory and technical
solutions exclusively serving the Life Science industry, is
pleased to announce that Evan Edwards has been promoted
to President. This organizational change allows Kymanox
to amplify the customer experience and further benefit
from Evan’s expertise in innovation and leadership. This
move provides further focus on operational processes for
Kymanox and positions Stephen M. Perry, CEO and Founder, to
focus on longer term strategic initiatives and
transformative business partnerships.
Evan brings a depth of experience and expertise to his
new role, having previously held leadership positions at
Kymanox the last four years including recently as Chief
Innovation Officer and also in the Life Science industry for over
two decades. He is a proven leader and inventor with a track
record of driving growth, commercialization, and innovation in
translational medicine.
"We are thrilled to elevate Evan to President of Kymanox," said
Perry. "His experience and continued leadership will be
invaluable as we continue to professionalize and scale our
unique platform. We are poised to grow both in market segments
and geographically – and this leadership evolution allows the
company to remain nimble, which is critically important for
any business."
As President, Evan will be responsible for overseeing the
company's near-term operations and driving strategic growth
initiatives. He will work closely with the rest of the Kymanox
Executive Leadership Team, and other leadership groups within
the organization, to ensure Kymanox continues to deliver
exceptional value to its clients and to support the CEO with
long-term strategic planning and market positioning – all to
ultimately benefit patients-in-need.
"I am honored to serve the Kymanox team as President," said
Evan. "I look forward to working with our talented team to
continue to deliver innovative solutions to our clients, supporting
them in the pursuit of regulatory approval and
commercialization of their products, and to drive continued
growth opportunities for the company."
About Kymanox®: Kymanox has proven,
collaborative, end-to-end solutions that help bring Life Science
products to the market – and keep them there. We are a global
professional services organization that supports comprehensive drug
development with integrated science, engineering, compliance (e.g.,
QA/RA), and technical project management. Our work across small and
large molecules, medical devices, and combination products affords
us a wholly unique advantage. With our diverse team of experts,
Kymanox helps clients navigate commercialization challenges that
arise throughout a product’s life cycle – from early development to
post-market – with optimized safety, quality, efficacy, and
accessibility. We strive to advance Life Science innovation through
insightful solutions and collaboration…because patients deserve
better. Kymanox was founded in 2004 and is headquartered in
Morrisville, North Carolina USA. Kymanox is backed by WestView
Capital Partners, a Boston-based growth equity firm. For more
information, visit http://www.kymanox.com/.
Matt Neighoff
Kymanox
919.802.5677
matt.neighoff@kymanox.com